Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program
Affiliations
- PMID: 32832831
- PMCID: PMC7434089
- DOI: 10.1200/po.18.00011
Abstract
Purpose: Evidence-based guidelines inform treatment decisions for patients for whom germline genetic information is available. Our real-time tumor sequencing program, which makes precision treatment decisions for patients with cancer, produces matched germline information, providing a unique opportunity to efficiently implement pharmacogenetics and benefit patients.
Methods: The germline genetic database from the Michigan Oncology Sequencing (MI-Oncoseq) program was searched for 21 clinically actionable polymorphisms in five cancer-relevant genes: TPMT, DPYD, CYP2C19, CYP3A5, and UGT1A1. Residual germ line DNA was sent to an external Clinical Laboratory Improvement Amendments-approved laboratory for confirmatory genotyping. The medical records of MI-Oncoseq patients with actionable phenotypes were searched for receipt of relevant drugs and to determine whether having genetic information at the time of treatment would have led to a treatment recommendation.
Results: All nine variants in TPMT, DPYD, and CYP2C19 that were detected in MI-Oncoseq were confirmed by external genotyping. Genotype determinations could not be made for CYP3A5*3, UGT1A1*28, or UGT1A1*80. On the basis of retrospective assessment of 115 adult and pediatric patient records, 4.3% (n = 5) had a potentially clinically actionable phenotype for TPMT, DPYD, or CYP2C19 and received a relevant medication. After accounting for differences in adult and pediatric recommendations, three of these patients could have received a treatment recommendation at the time of prescribing.
Conclusion: Germline genotype determinations for TPMT, DPYD, and CYP2C19 can be used to make evidence-based treatment recommendations in MI-Oncoseq patients. Although the proportion of patients for whom recommendations can be made is small, this added value to MI-Oncoseq and patient care comes at no additional genotyping cost. Pharmacogenetic assessment should be integrated into tumor sequencing programs that genotype matched germline DNA; however, the complexity and additional cost of implementing pharmacogenetics remain challenging.
Similar articles
- Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.Cancer. 2018 Jul 15;124(14):3052-3065. doi: 10.1002/cncr.31382. Epub 2018 May 9.PMID: 29742281 Free PMC article.
- Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.Clin Pharmacol Ther. 2019 Oct;106(4):866-873. doi: 10.1002/cpt.1489. Epub 2019 Jun 12.PMID: 31038729 Free PMC article.
- Considerations for rare variants in drug metabolism genes and the clinical implications.Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):873-84. doi: 10.1517/17425255.2014.903239. Epub 2014 Mar 28.PMID: 24673405 Review.
- Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.J Mol Diagn. 2016 Jan;18(1):109-23. doi: 10.1016/j.jmoldx.2015.08.005. Epub 2015 Nov 24.PMID: 26621101 Free PMC article.
- Using germline genotype in cancer pharmacogenetic studies.Pharmacogenomics. 2009 Mar;10(3):489-93. doi: 10.2217/14622416.10.3.489.PMID: 19650256 Free PMC article. Review.
No hay comentarios:
Publicar un comentario